H.C Wainwright and Citizens Raise PT on DBV Technologies (DBVT) Following Phase 3 VITESSE Trial Result
On December 17, 2025, H.C. Wainwright raised its price target on DBV Technologies S.A. (NASDAQ:DBVT) from $35 to $40, while reiterating a “Buy” rating, The Fly reported.






